News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–14
Matches
14
Sources here
4
Companies here
1
Search results Stored financial headlines

Active search

14 matching headlines

Ticker or company: AYTUMain company stories
Clear
Latest

Stock Titan Deals and strategy

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake

An investor, Laurence W. Lytton, and the Lytton-Kambara Foundation have each reported a 4.99% beneficial ownership stake in Aytu BioPharma (AYTU), according to a recent Schedule 13G/A filing. Each party beneficially owns 545,946 shares, consisting of common stock and warrants, with all voting and dispositive powers shared. This ownership percentage is based on 10,733,208 shares outstanding as of …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
TradingKey Earnings Main company 🇺🇸 United States

Aytu Biopharma Inc (AYTU) Stock News Today

This article from TradingKey provides a stock overview for Aytu Biopharma Inc (AYTU), displaying its current stock price, market cap, and a note indicating that more news, earnings, and analyst ratings are coming soon. It also lists various financial and analytical tools available on …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates

Aytu Biopharma Inc (AYTU) has an earnings forecast score of 8.00, ranking 58th in the Pharmaceuticals industry, with an average analyst price target of $8.00. Analysts largely recommend a "Buy" for AYTU, projecting future revenue of $12.28M and an EPS of -$0.33 for the …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Earnings Main company 🇺🇸 United States

Aytu Biopharma Inc (AYTU) Financial Health: Profitability & Balance Sheet Analysis

Aytu Biopharma Inc (AYTU) currently holds a financial score of 7.93, ranking 88 out of 155 in the Pharmaceuticals industry, indicating stable financial status and high operating efficiency. Despite this, its latest quarterly revenue decreased by 32.74% year-over-year, and net profit saw a significant …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Aytu Biopharma Inc (AYTU) by business segment. As of the latest update on April 6, the company's ADHD portfolio accounts for 87.15% of its revenue, followed by its Pediatric portfolio at 11.14%. EXXUA and "Other" categories contribute …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Aytu Biopharma Inc (AYTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aytu Biopharma Inc (AYTU), detailing its price momentum, support and resistance levels, and insights from various technical indicators and moving averages. As of July 29, 2026, AYTU's price momentum score is 3.08, and the stock is trading …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

AYTU|Aytu Biopharma Inc|Price:2.135|Chg%:+0.075

This article provides a detailed financial overview of Aytu Biopharma Inc. (AYTU), including its latest earnings report from May 13, 2026, and historical quarterly and annual financial indicators. It covers key metrics such as EPS, revenue, net profit, margins, debt-to-assets ratio, and various balance …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Aytu Biopharma Inc (AYTU) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Aytu Biopharma Inc (AYTU) based on its current stock price and financial metrics. As of July 29, 2026, the company's valuation score is 8.95, ranking 65th in the Pharmaceuticals industry, with a P/E ratio of -0.45. Key …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga España Earnings Main company 🇺🇸 United States

Aytu BioPharma Market Sentiment

This article analyzes market sentiment for Aytu BioPharma (AYTU), covering analyst consensus, short interest, options flow, and insider activity. Analysts currently have a "Buy" consensus with an average price target significantly above the current stock price, and there's a declining short interest. Recent insider …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Aytu Biopharma Inc (AYTU) Cash Flow

This article provides a detailed cash flow statement for Aytu Biopharma Inc (AYTU), covering annual and quarterly data across operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and AYTU's performance in each category, such as …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Deals and strategy Main company 🇺🇸 United States

Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on Aytu Biopharma Inc's (AYTU) dividends and stock splits. It indicates that AYTU has not distributed any dividends in the past five years but has undergone several stock mergers, including two 20-to-1 mergers in January 2023 and two 10-to-1 …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Aytu Biopharma Inc (AYTU) Income Statement - TradingKey

This page from TradingKey provides a detailed quarterly and annual income statement for Aytu Biopharma Inc (AYTU), covering total revenue, operating expenses, special income, and net income, along with year-over-year comparisons. It includes financial data from FY2012Q1 through FY2026Q3, highlighting trends and specific figures …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Aytu BioPharma, Inc. Revenue Breakdown – NASDAQ:AYTU

Aytu BioPharma, Inc. (NASDAQ: AYTU) generated $66.38 million in revenue last year, primarily from its Rx segment. This segment was also its top performer, contributing the entirety of the revenue, showing a slight increase from $65.18 million the previous year. The United States was …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

AYTU|Aytu Biopharma Inc|Price:2.160|

Aytu Biopharma Inc. (AYTU) has healthy fundamentals and high growth potential, though its valuation is considered fairly valued within the Pharmaceuticals industry. Analysts have rated it as "Buy" with a high price target, but the stock price is expected to trend down in the …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context